Celeris Therapeutics: Funding, Investors & Team (Sep 2026)
Celeris Therapeutics is a deep learning company that uses innovative, computer-based methods to degrade undruggable targets. The platform Celeris One exploits the potential of degrader technologies with accurate predictions of biomolecular interactions and the expansion of chemical space. Celeris One uses methods such as Graph Representation Learning, Active Learning, Data Augmentation, and Generative Models to expand the chemical space and leverage sparse and heterogeneous data. This leads to the design of PROTACs, Molecular Glues, and Small Molecule.
Celeris Therapeutics has raised $4.1M across 2 funding rounds on record, the most recent a Seed of $3.4M announced in Feb 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Celeris Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2022.
Celeris Therapeutics Funding Rounds
Celeris Therapeutics raised $700k in a Pre-Seed announced in Jul 2021.
7 months later, a Seed of $3.4M was announced in Feb 2022.
Celeris Therapeutics Founders and Leadership Team
Contact details for the Celeris Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Celeris Therapeutics Funding Compared to Other Biotechnology Startups
Celeris Therapeutics' latest round of $3.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Celeris Therapeutics in Biotechnology and Graz
Companies Similar to Celeris Therapeutics
Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell…
VALANX Biotech creates a unique method of attaching proteins to specific sites for use in treatments,…
aTension.life is a company dedicated to improving the diagnosis and treatment of hypertension using precision…
Millions of people worldwide suffer from brain-related issues that can already be addressed with the latest…
Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious…
The patented technology developed by Lignovations allows for the creation of lignin particles in the…
Sarcura creates a machine platform for the mass production of customized cell therapies in industry. Our goal…
Arkeon Bio is a biotechnology company that captures CO2 from industry and converts inorganic gases into…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
Celeris Therapeutics Funding FAQs
What does Celeris Therapeutics do?
Celeris Therapeutics is a deep learning company that uses innovative, computer-based methods to degrade undruggable targets. The platform Celeris One exploits the potential of degrader technologies with accurate predictions of biomolecular interactions and the expansion of chemical space. Celeris One uses methods such as Graph Representation Learning, Active Learning, Data Augmentation, and Generative Models to expand the chemical space and leverage sparse and heterogeneous data. This leads to the design of PROTACs, Molecular Glues, and Small Molecule.
How much funding has Celeris Therapeutics raised?
Celeris Therapeutics has raised $4.1M across 2 rounds on record. The most recent is a Seed of $3.4M announced in Feb 2022.
When did Celeris Therapeutics last raise funding?
Celeris Therapeutics' most recent funding round on record is a Seed of $3.4M, announced in Feb 2022.
Who is the CEO of Celeris Therapeutics?
Christopher Trummer is listed as CEO at Celeris Therapeutics.
Where is Celeris Therapeutics headquartered?
Celeris Therapeutics is based in Graz, Steiermark, Austria.
How many employees does Celeris Therapeutics have?
Celeris Therapeutics is in the 11-50 employee band.
How does Celeris Therapeutics' funding compare to other Biotechnology startups?
Celeris Therapeutics' latest round of $3.4M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Celeris Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Celeris Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.